A comparison of the estimated costs of erlotinib, docetaxel and pemetrexed for the second-line treatment of non-small cell lung cancer from the German healthcare perspective

Journal of Medical Economics

Volumn 10, Issue 3, 2007, Pages 255-271

  Kotowa, Wioletta ^a   Gatzemeier, Ulrich ^b   Pirk, Olaf ^a   Gabriel, Anja ^a   Heigener, David ^b  

^a Fricke & Pirk GmbH   (Germany)

^b KRANKENHAUS GROSSHANSDORF   (Germany)

Author keywords

Cost comparison; Docetaxel; Erlotinib; NSCLC; Pemetrexed

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDIARRHEAL AGENT; ANTIFUNGAL AGENT; CORTICOSTEROID; CYANOCOBALAMIN; DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; FOLIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; PEMETREXED; SEROTONIN ANTAGONIST;

ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER CENTER; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEHYDRATION; DIARRHEA; DRUG COST; DRUG ERUPTION; FEMALE; GERMANY; HEALTH INSURANCE; HUMAN; INFECTION; LUNG NON SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; RESOURCE ALLOCATION; SEIZURE; SENSITIVITY ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; VOMITING;

EID: 34748851391     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990701438637     Document Type: Article

References (32)

1. Cancer in Germany: Incidence and Trends. 5th edn. Saarbrücken, Germany: Association of the Epidemiological Cancer Register in Germany & the Robert Koch Institute, 2006 [in German].
2. Häussinger KE, Kohlhaufl M. Manual: Tumours of the Lung and Mediastinum. Munich Tumour Centre and W. Zuckschwerdt Verlag Munich Germany (2003) [in German].
3. Carbone DP. The biology of lung cancer. Seminars in Oncology 1997; 24: 388-401.
4. Ärzte Zeitung. With erlotinib doctors hope for a breakthrough in lung cancer. 23 March 2005 [in German].
5. Association of the Scientific Medical Societies in Germany. Treatment of non-small-cell lung cancer. AWMF Guideline Register. No. 032/007, January 2004 [in German].
6. Felip E, Stahel RA, Pavlidis N. ESMO Guidelines Taskforce. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of non-small-cell lung cancer (NSCLC). Annals of Oncology 2005; 16(Suppl. 1): i28-i29.
7. Pfister DG, Johnson DH, Assoil CG et al. American Society of Clinical Oncology. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. Journal of Clinical Oncology 2004; 22: 330-353.
8. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Journal of Clinical Oncology 2000; 18: 2095-2103.
9. Shepherd FA, Dancey J, Ramlau R et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Classic Papers and Current Comments 2001; 6: 87-96.
10. Dancey J, Shepherd FA, Gralla et al. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 2004; 43: 183-194.
11. Hanna N, Shepherd FA, Fossella F et al. Randomized phase III trial of pemetrexed vs docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. Journal of Clinical Oncology 2004; 22: 1589-1597.
12. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Seminars in Oncology 2003; 30(3 Suppl. 7): 3-14.
13. Shepherd FA, Pereira JR, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. New England Journal of Medicine 2005; 353: 123-132.
14. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group study BR.21. Journal of Clinical Oncology 2006; 24: 3831-3837.
15. Ramalingam S, Sandler AB: Salvage therapy for advanced non-small cell lung cancer: factors influencing treatment selection. The Oncologist 2006; 11: 655-665.
16. National Cancer Institute of Canada Clinical Trials Group (NCIC CTG). A randomized placebo controlled study of OSI-774 (Tarceva™) in patients with incurable stage IIIB/IV non-small cell lung cancer who have failed standard therapy for advanced or metastatic disease. NCIC CTG Protocol Number: BR.21. Protocol Date: 10 August 2001. Data on file, Hoffmann-La Roche, 2001.
17. BR.21. Biometrie Report. Data on file, Hoffmann-La Roche.
18. Stynes G, Aristides M, Rosell R et al. Improved toxicity profile of pemetrexed vs docetaxel in previously treated non-small cell lung cancer patients translates to cost savings in Spain. In: 7th Annual International Society for Pharmacoeconomics and Outcomes Research - European Congress; Value in Health (2004) 7: Poster presentation (abstract no. PCN30). www.ispor.org/RESEARCH_STUDY_DIGEST/details.asp [accessed 20 December 2005].
19. Tarceva® 150 mg. German prescribing information (revision date September 2005). http://www.fachinfo.de/ [accessed 20 October 2005].
20. Taxotere® 80 mg. German prescribing information (revision date November 2005). http://www.fachinfo.de/ [accessed 20 December 2005].
21. Alimta®. German prescribing information (revision date January 2006). http://www.fachinfo.de/ [accessed 6 February 2006].
22. Association of the Scientific Medical Societies in Germany. Principles of antineoplastic chemotherapy and hormone therapy. AWMF Guideline Register. No. 032/002, last updated January 2005 [in German].
23. Müller RP, Seegenschmiedt MH, Höffken K et al. Common Toxicity Criteria (CTC): documentation of side effects in oncology. Deutsches Ärzteblatt 1999; 96: A489-B-433, C-397 [in German].
24. National Association of Statutory Health Insurance Physicians. Uniform fee scale for medical services EBM 2000 PLUS. http://www.kbv.de/ ebm2000plus/EBMGesamt.htm, revision date June 2005 [accessed 21 September 2006] [in German].
25. Schleswig-Holstein Association of Statutory Health Insurance Physicians. Opinions differ on the point value Nordlicht Aktuell 2005; 3: 12-16 [in German].
26. Institut für Ärzte und Apotheker GmbH [Institute of Physicians and Pharmacists]. IfAP Index Praxis. Bad Saarow, revision date 1 April 2005 [in German].
27. Fallpauschalen-Katalog [flat case rate schedule]. http://www.g-drg.de/ service/download/veroeff_2005/Endfassung_FallpauschalenKatalog_040915_1500.pdf [accessed 15 October 2005] [in German].
28. Institut für das Entgeltsystem im Krankenhaus gGmbH [Institute for the hospital payment system] (InEK). 2005: German Diagnosis Related Groups (G-DRG) version 2005 [in German].
29. National PBM Drug Monograph-Pemetrexed (Alimta®). Available at: http://www.pbm.va.gov/monograph/765rtwPemetrexedMono.pdf [accessed 20 December 2005].
30. Heimig F: Classification and valuation. Presentation of results in favour of the self-governing partners under the Hospital Financing Act §17b. G-DRGs 2006 Siegburg, 24 August 2005 [in German].
31. DKG-NT: German Hospital Federation schedule of charges for services performed and for cost reimbursement by the physician to the hospital. Stuttgart, Germany: W. Kohlhammer Verlag, (2002) [in German].
32. Fossella F, DeVore R, Kerr R et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. Journal of Clinical Oncology 2000; 18: 2354-2362.